Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg...
FDA Drug Recall #D-0077-2021 — Class II — November 1, 2020
Recall Summary
| Recall Number | D-0077-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 1, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Preferred Pharmaceuticals, Inc. |
| Location | Anaheim, CA |
| Product Type | Drugs |
| Quantity | 99 bottles (9990 Extended Release Tablets) |
Product Description
Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg: Time-Cap Labs, Inc.; Farmingdale, NY, NDC #: 68788-6932-1, Preferred Pharmaceuticals, Inc.
Reason for Recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Distribution Pattern
Distributed to two physician's offices located in FL.
Lot / Code Information
E0620F, Exp.12/31/2021; G2020M Exp., 04/30/2022
Other Recalls from Preferred Pharmaceuticals, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0443-2026 | Class II | Artificial Tears Lubricant Eye Drops (glycerin ... | Mar 25, 2026 |
| D-0239-2026 | Class II | Ondansetron ODT Tablets, USP 4mg, 1x10 unit do... | Nov 17, 2025 |
| D-0391-2025 | Class II | Clindamycin Hydrochloride Capsules, USP, 300mg,... | Apr 18, 2025 |
| D-0647-2024 | Class II | Ibuprofen Tablets, USP 400mg, Generic for Motri... | Aug 8, 2024 |
| D-0505-2024 | Class II | Duloxetine Delayed-Release Cap USP 30mg, 30-cou... | May 10, 2024 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.